Non-Dilated Left Ventricular Cardiomyopathy vs. Dilated Cardiomyopathy: Clinical Background and Outcomes

Figures

• 

  Figure 1. Patient flow. BSA, body surface area; DCM, dilated cardiomyopathy; LV, left ventricular; LVDd, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; NDLVC–REF, non‐dilated left ventricular cardiomyopathy and reduced left ventricular ejection fraction. *LV dilatation defined LVDd/BSA of >31 in men or >34 in women.

• 

  Figure 2. Kaplan–Meier curve for primary endpoint (A) and secondary endpoint (B). DCM, dilated cardiomyopathy; NDLVC–REF, non‐dilated left ventricular cardiomyopathy and reduced left ventricular ejection fraction.

• 

  Figure 3. Transition of LVEF (A) and LVDd (B) after diagnosis. DCM, dilated cardiomyopathy; LVDd, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NDLVC–REF, non‐dilated left ventricular cardiomyopathy and reduced left ventricular ejection fraction.

• 

  Figure 4. Kaplan–Meier curve in NDLVC–REF patients with and without left ventricular dilatation after diagnosis. LV, left ventricular; NDLVC–REF, non‐dilated left ventricular cardiomyopathy and reduced left ventricular ejection fraction.